Company:  EYEPOINT PHARMACEUTICALS, ... (EYPT)
Form Type:  424B5
Filing Date:  1/19/2011 
CIK:  0001314102 
Address:  480 PLEASANT STREET
SUITE B300
 
City, State, Zip:  WATERTOWN, Massachusetts 02472 
Telephone:  617-926-5000 
Fiscal Year:  12/31 
Last Trade
Last Trade: 
$10.53  
Change: 
0.02 (0.19%)  
Trade Time: 
Aug 05  
Market Cap: 
$358.52M
Trade EYPT now with 

© 2022  
Description of Business
We are a pharmaceutical company committed to developing and commercializing innovative therapeutics to help improve the lives of patients with serious eye disorders. Our pipeline leverages our proprietary Durasert® technology for sustained intraocular drug delivery including EYP-1901, a potential six-month anti-VEGF treatment initially targeting wet age-related macular degeneration ("wet AMD"), the leading cause of vision loss among people 50 years of age and older in the United States. We also have two commercial products: YUTIQ®, a once every three-year treatment for chronic non-infectious uveitis affecting the posterior segment of the eye, and DEXYCU®, a single dose treatment for postoperative inflammation following ocular surgery. We are also advancing YUTIQ 50, a potential six-month treatment for non-infectious uveitis affecting the posterior segment of the eye, one of the leading causes of blindness under a supplemental New Drug Application ("sNDA") strategy.
Register and access this filing in:     
  FORM 424B5
    TABLE OF CONTENTS
    ABOUT THIS PROSPECTUS SUPPLEMENT
    Risk Factors
    The Offering
    RISK FACTORS
    NOTE REGARDING FORWARD-LOOKING STATEMENTS
    USE OF PROCEEDS
    DILUTION
    DESCRIPTION OF SECURITIES
    PLAN OF DISTRIBUTION
    LEGAL MATTERS
    WHERE YOU CAN FIND MORE INFORMATION
      INCORPORATION OF CERTAIN DOCUMENTS BY REFERENCE
    RISK FACTORS
    USE OF PROCEEDS
    DESCRIPTION OF SECURITIES
    EXPERTS